LOTTE Biologics

LOTTE Biologics is a global CDMO providing integrated development and manufacturing solutions across the United States and South Korea.

Through its Dual Hub Service model, LOTTE Biologics supports clients across the biopharmaceutical lifecycle—from early-stage development and clinical supply through commercial manufacturing—while enhancing supply security, manufacturing flexibility, and consistent quality across regions.

At the Syracuse Bio Campus in New York, LOTTE Biologics provides established GMP manufacturing capabilities backed by more than 62 global regulatory approvals. The campus offers 40,000 L of capacity across eight 5,000 L stainless steel bioreactors, along with analytical and warehouse infrastructure. Integrated bioconjugation capabilities, including antibody-drug conjugates (ADCs), enable a streamlined pathway from biologic drug substance manufacturing through bioconjugation within a single campus.

In South Korea, the Songdo Bio Campus is designed as a next-generation, large-scale biologics manufacturing hub, with 120,000 L of manufacturing capacity across eight 15,000 L stainless steel bioreactors, complemented by a flexible 3,000 L bioreactor configuration to support diverse manufacturing needs.

With capabilities spanning monoclonal antibodies, fusion proteins, multispecific modalities, and bioconjugation, LOTTE Biologics combines scientific expertise, advanced technologies, scalable manufacturing, and a partnership-driven approach to deliver flexible solutions tailored to the needs of each client and program.

Guided by the vision “Possibilities Beyond Limits,” LOTTE Biologics is committed to being a trusted long-term partner in advancing innovative biologics for patients worldwide.